Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study
Objective To examine the course of interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in France on treatment with Janus kinase inhibitors (JAKis) using the MAJIK-SFR registry.Methods Prospective national multicentre observational study identifying patients with RA-ILD from the M...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/11/1/e005062.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556933835751424 |
|---|---|
| author | Adeline Ruyssen-Witrand Jacques-Eric Gottenberg Philippe Dieude Rene-Marc Flipo Jerome Avouac Emanuelle Dernis Anne Tournadre Marie-Elise Truchetet Raphaele Seror André Ramon Nicolas Roux André Basch Pascal Chazerain Fabienne Coury-Lucas Richard Damade Pierre-Antoine Juge Thao Pham Clément Prati Olivier Brocq Jean Hugues Salmon Christian hubert roux Félicien Triboulet Charles Leské Émilie Shipley |
| author_facet | Adeline Ruyssen-Witrand Jacques-Eric Gottenberg Philippe Dieude Rene-Marc Flipo Jerome Avouac Emanuelle Dernis Anne Tournadre Marie-Elise Truchetet Raphaele Seror André Ramon Nicolas Roux André Basch Pascal Chazerain Fabienne Coury-Lucas Richard Damade Pierre-Antoine Juge Thao Pham Clément Prati Olivier Brocq Jean Hugues Salmon Christian hubert roux Félicien Triboulet Charles Leské Émilie Shipley |
| author_sort | Adeline Ruyssen-Witrand |
| collection | DOAJ |
| description | Objective To examine the course of interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in France on treatment with Janus kinase inhibitors (JAKis) using the MAJIK-SFR registry.Methods Prospective national multicentre observational study identifying patients with RA-ILD from the MAJIK-SFR registry. Pulmonary assessment data were collected at JAKi initiation and follow-up visits (6 months, 12 months and a median of 21 months postinclusion), including chest high-resolution CT (HRCT), pulmonary function tests (forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO)), acute exacerbations of ILD, respiratory infections and lung cancers.Results We enrolled 42 patients (26 women, 62%) with RA-ILD with a mean age of 61±13 years and a mean disease duration of 16±10 years. Compared with the 778 RA patients without ILD from the MAJIK registry, RA-ILD patients were older, displayed more severe and active disease and had more prevalent comorbidities. Non-specific interstitial pneumonia and usual interstitial pneumonia accounted for 46% and 43% of the chest HRCT ILD patterns, respectively. No significant changes in FVC and DLCO were observed during the follow-up period. Chest HRCT lesions remained stable in 69% of patients. Progressive ILD was identified in 8 patients (19%). 16 (38%) respiratory tract infections were observed. Only one acute regressive exacerbation of ILD was noted, and no lung cancer was diagnosed. No deaths occurred. JAKi was discontinued in 17 patients including 8 for inefficacy on joint involvement and 5 for intolerance.Conclusion The analysis indicates stability of RA-ILD in patients treated with JAKi. The tolerance profile of JAKi in this higher risk population did not reveal new safety signal. |
| format | Article |
| id | doaj-art-4fe97f5a9a2f4ea1846c7c531c9f7b8e |
| institution | Kabale University |
| issn | 2056-5933 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-4fe97f5a9a2f4ea1846c7c531c9f7b8e2025-01-07T04:45:12ZengBMJ Publishing GroupRMD Open2056-59332025-01-0111110.1136/rmdopen-2024-005062Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort studyAdeline Ruyssen-Witrand0Jacques-Eric Gottenberg1Philippe Dieude2Rene-Marc Flipo3Jerome Avouac4Emanuelle Dernis5Anne Tournadre6Marie-Elise Truchetet7Raphaele Seror8André Ramon9Nicolas Roux10André Basch11Pascal Chazerain12Fabienne Coury-Lucas13Richard Damade14Pierre-Antoine Juge15Thao Pham16Clément Prati17Olivier Brocq18Jean Hugues Salmon19Christian hubert roux20Félicien Triboulet21Charles Leské22Émilie Shipley23Service de Rhumatologie, Centre hospitalier universitaire Purpan, Université Toulouse III Paul-Sabatier, Toulouse, FranceService de Rhumatologie, Hôpital universitaire de Hautepierre, Université de Strasbourg, Strasbourg, FranceService de Rhumatologie, Hôpital Bichat-Claude Bernard, APHP, Université Paris Cité, Paris, FranceService de Rhumatologie, Hôpital Roger-Salengro, Université de Lille, Lille, FranceService de Rhumatologie, Hôpital Cochin, APHP-Centre Université Paris Cité, Paris, FranceService de Rhumatologie, Centre hospitalier du Mans, Le Mans-Université, Le Mans, FranceService de Rhumatologie, Centre Hospitalier Universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, FranceService de Rhumatologie, CHU Bordeaux, Bordeaux, FranceService de Rhumatologie, Hôpital universitaire Bicêtre, Université Paris-Saclay, Assistance Publique-Hôpitaux de Par, Le Kremlin Bicêtre, FranceService de Rhumatologie, Centre hospitalier universitaire de Dijon, Université de Dijon, Dijon, FranceService de Rhumatologie, Hôpital Robert Schuman, Metz, FranceService de Rhumatologie, Clinique de l`Infirmerie Protestante, Lyon, FranceService de Rhumatologie, Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, Île-de-France, FranceService de Rhumatologie, Hôpital Lyon-Sud, Université Claude-Bernard Lyon I, Hospices Civils de Lyon, Lyon, FranceService de Rhumatologie, Hôpital Louis-Pasteur, Université d’Orléans, Chartres, FranceService de Rhumatologie, Hôpital Bichat-Claude Bernard, APHP, Université Paris Cité, Paris, FranceService de Rhumatologie, Hôpital universitaire Sainte-Marguerite, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Marseille, FranceService de Rhumatologie, Centre hospitalier régional universitaire Jean-Minjoz, Université de Franche-Comté, Besançon, FranceService de Rhumatologie, Centre hospitalier Princesse-Grâce, MonacoService de Rhumatologie, Centre hospitalier universitaire de Reims, Université de Reims Champagne-Ardenne, Reims, FranceService de Rhumatologie, Hôpital Pasteur 2, Université Côte d`Azur, Nice, FranceService de Rhumatologie, Hôpital Cochin, APHP-Centre Université Paris Cité, Paris, FranceService de Rhumatologie, Centre hospitalier de Cholet, Université d’Angers, Cholet, FranceService de Rhumatologie, Centre hospitalier Dax-Côte d’Argent, Université de Bordeaux, Dax, FranceObjective To examine the course of interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in France on treatment with Janus kinase inhibitors (JAKis) using the MAJIK-SFR registry.Methods Prospective national multicentre observational study identifying patients with RA-ILD from the MAJIK-SFR registry. Pulmonary assessment data were collected at JAKi initiation and follow-up visits (6 months, 12 months and a median of 21 months postinclusion), including chest high-resolution CT (HRCT), pulmonary function tests (forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO)), acute exacerbations of ILD, respiratory infections and lung cancers.Results We enrolled 42 patients (26 women, 62%) with RA-ILD with a mean age of 61±13 years and a mean disease duration of 16±10 years. Compared with the 778 RA patients without ILD from the MAJIK registry, RA-ILD patients were older, displayed more severe and active disease and had more prevalent comorbidities. Non-specific interstitial pneumonia and usual interstitial pneumonia accounted for 46% and 43% of the chest HRCT ILD patterns, respectively. No significant changes in FVC and DLCO were observed during the follow-up period. Chest HRCT lesions remained stable in 69% of patients. Progressive ILD was identified in 8 patients (19%). 16 (38%) respiratory tract infections were observed. Only one acute regressive exacerbation of ILD was noted, and no lung cancer was diagnosed. No deaths occurred. JAKi was discontinued in 17 patients including 8 for inefficacy on joint involvement and 5 for intolerance.Conclusion The analysis indicates stability of RA-ILD in patients treated with JAKi. The tolerance profile of JAKi in this higher risk population did not reveal new safety signal.https://rmdopen.bmj.com/content/11/1/e005062.full |
| spellingShingle | Adeline Ruyssen-Witrand Jacques-Eric Gottenberg Philippe Dieude Rene-Marc Flipo Jerome Avouac Emanuelle Dernis Anne Tournadre Marie-Elise Truchetet Raphaele Seror André Ramon Nicolas Roux André Basch Pascal Chazerain Fabienne Coury-Lucas Richard Damade Pierre-Antoine Juge Thao Pham Clément Prati Olivier Brocq Jean Hugues Salmon Christian hubert roux Félicien Triboulet Charles Leské Émilie Shipley Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study RMD Open |
| title | Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study |
| title_full | Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study |
| title_fullStr | Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study |
| title_full_unstemmed | Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study |
| title_short | Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study |
| title_sort | evaluation of rheumatoid arthritis associated interstitial lung disease in patients treated with jak inhibitors a majik sfr cohort study |
| url | https://rmdopen.bmj.com/content/11/1/e005062.full |
| work_keys_str_mv | AT adelineruyssenwitrand evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT jacquesericgottenberg evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT philippedieude evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT renemarcflipo evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT jeromeavouac evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT emanuelledernis evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT annetournadre evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT marieelisetruchetet evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT raphaeleseror evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT andreramon evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT nicolasroux evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT andrebasch evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT pascalchazerain evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT fabiennecourylucas evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT richarddamade evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT pierreantoinejuge evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT thaopham evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT clementprati evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT olivierbrocq evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT jeanhuguessalmon evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT christianhubertroux evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT felicientriboulet evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT charlesleske evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy AT emilieshipley evaluationofrheumatoidarthritisassociatedinterstitiallungdiseaseinpatientstreatedwithjakinhibitorsamajiksfrcohortstudy |